Role of chemokines in tumor growth

Cancer Letters

Volumn 256, Issue 2, 2007, Pages 137-165

  Raman, Dayanidhi ^a   Baugher, Paige J ^a   Thu, Yee Mon ^a   Richmond, Ann ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Chemokines; Chronic inflammation; Stromal cells; Tumor growth

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CX3C CHEMOKINE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL4 CHEMOKINE; CXCL6 CHEMOKINE; CXCL7 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FRACTALKINE; GAMMA CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN S 100; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN CORRELATED CHEMOKINE 1;

ACIDITY; ADAPTIVE IMMUNITY; ANGIOGENESIS; AUTOCRINE EFFECT; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER INVASION; CARCINOMA; CELL INFILTRATION; CELL INVASION; COLORECTAL CANCER; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG TARGETING; FIBROBLAST; HUMAN; IMMUNOSURVEILLANCE; INFLAMMATION; LEUKOCYTE MIGRATION; LIGAND BINDING; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; OVARY CARCINOMA; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN FUNCTION; RECEPTOR BINDING; SHORT SURVEY; STROMA CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR PROMOTION; TUMOR VASCULARIZATION; UPREGULATION;

EID: 34548665711     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.05.013     Document Type: Review

References (280)

1. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
2. Coussens L.M., and Werb Z. Inflammatory cells and cancer: think different!. J. Exp. Med. 193 (2001) F23-F26
3. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
4. van Kempen L.C., de Visser K.E., and Coussens L.M. Inflammation, proteases and cancer. Eur. J. Cancer 42 (2006) 728-734
5. Balkwill F., and Coussens L.M. Cancer: an inflammatory link. Nature 431 (2004) 405-406
6. Robinson S.C., and Coussens L.M. Soluble mediators of inflammation during tumor development. Adv. Cancer Res. 93 (2005) 159-187
7. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., and Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 72 (2006) 1605-1621
8. Szlosarek P., Charles K.A., and Balkwill F.R. Tumour necrosis factor-alpha as a tumour promoter. Eur. J. Cancer 42 (2006) 745-750
9. Wang D., Yang W., Du J., Devalaraja M.N., Liang P., Matsumoto K., et al. MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene 19 (2000) 4647-4659
10. Dhawan P., and Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 72 (2002) 9-18
11. Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J. Exp. Med. 203 (2006) 941-951
12. Cha Y.I., and Dubois R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu. Rev. Med. (2006)
13. Knudson Jr. A.G. Mutation and cancer in man. Cancer 39 (1977) 1882-1886
14. Karin M. Nuclear factor-kappa B in cancer development and progression. Nature 441 (2006) 431-436
15. Knudson A.G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1 (2001) 157-162
16. Rangarajan A., Hong S.J., Gifford A., and Weinberg R.A. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6 (2004) 171-183
17. Sica A., Saccani A., Bottazzi B., Polentarutti N., Vecchi A., van Damme J., et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 164 (2000) 762-767
18. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5 (2005) 263-274
19. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin. Cancer Biol. 16 (2006) 38-52
20. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7 (2007) 41-51
21. Bottazzi B., Polentarutti N., Acero R., Balsari A., Boraschi D., Ghezzi P., et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science 220 (1983) 210-212
22. Bhowmick N.A., Neilson E.G., and Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 432 (2004) 332-337
23. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 (2005) 335-348
24. Orimo A., and Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5 (2006) 1597-1601
25. Kalluri R., and Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 6 (2006) 392-401
26. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
27. Vicari A.P., and Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 13 (2002) 143-154
28. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 5 (2003) 31-36
29. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 25 (2006) 357-371
30. Rot A., and von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22 (2004) 891-928
31. Baggiolini M., Dewald B., and Moser B. Human chemokines: an update. Annu. Rev. Immunol. 15 (1997) 675-705
32. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338 (1998) 436-445
33. Rossi D., and Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18 (2000) 217-242
34. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 (2000) 121-127
35. Hiratsuka S., Watanabe A., Aburatani H., and Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8 (2006) 1369-1375
36. Rafii S., and Lyden D. S100 chemokines mediate bookmarking of premetastatic niches. Nat. Cell Biol. 8 (2006) 1321-1323
37. Weinstein E.J., Head R., Griggs D.W., Sun D., Evans R.J., Swearingen M.L., et al. VCC-1, a novel chemokine, promotes tumor growth. Biochem. Biophys. Res. Commun. 350 (2006) 74-81
38. Liston A., and McColl S. Subversion of the chemokine world by microbial pathogens. Bioessays 25 (2003) 478-488
39. Crump M.P., Elisseeva E., Gong J., Clark-Lewis I., and Sykes B.D. Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10). FEBS Lett. 489 (2001) 171-175
40. Devalaraja M.N., and Richmond A. Multiple chemotactic factors: fine control or redundancy?. Trends Pharmacol. Sci. 20 (1999) 151-156
41. Zlotnik A. Chemokines and cancer. Int. J. Cancer 119 (2006) 2026-2029
42. Scotton C.J., Wilson J.L., Milliken D., Stamp G., and Balkwill F.R. Epithelial cancer cell migration: a role for chemokine receptors?. Cancer Res. 61 (2001) 4961-4965
43. Phillips R.J., Burdick M.D., Lutz M., Belperio J.A., Keane M.P., and Strieter R.M. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med. 167 (2003) 1676-1686
44. Ding Y., Shimada Y., Maeda M., Kawabe A., Kaganoi J., Komoto I., et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin. Cancer Res. 9 (2003) 3406-3412
45. Schimanski C.C., Schwald S., Simiantonaki N., Jayasinghe C., Gonner U., Wilsberg V., et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin. Cancer Res. 11 (2005) 1743-1750
46. Schimanski C.C., Bahre R., Gockel I., Muller A., Frerichs K., Horner V., et al. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br. J. Cancer 95 (2006) 210-217
47. Chen G.S., Yu H.S., Lan C.C., Chow K.C., Lin T.Y., Kok L.F., et al. CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br. J. Dermatol. 154 (2006) 910-918
48. Luker K.E., and Luker G.D. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 238 (2006) 30-41
49. Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382 (1996) 635-638
50. Ma Q., Jones D., Borghesani P.R., Segal R.A., Nagasawa T., Kishimoto T., et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. USA 95 (1998) 9448-9453
51. Balabanian K., Lagane B., Infantino S., Chow K.Y., Harriague J., Moepps B., et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 280 (2005) 35760-35766
52. Heesen M., Berman M.A., Charest A., Housman D., Gerard C., and Dorf M.E. Cloning and chromosomal mapping of an orphan chemokine receptor: mouse RDC1. Immunogenetics 47 (1998) 364-370
53. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382 (1996) 829-833
54. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., Arenzana-Seisdedos F., et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382 (1996) 833-835
55. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203 (2006) 2201-2213
56. Kumar S.M., Yu H., Edwards R., Chen L., Kazianis S., Brafford P., et al. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res. 67 (2007) 3177-3184
57. Schioppa T., Uranchimeg B., Saccani A., Biswas S.K., Doni A., Rapisarda A., et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 198 (2003) 1391-1402
58. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., and Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425 (2003) 307-311
59. E., Schutyser, Y. Su, Y. Yu, M. Gouwy, S. Zaja-Milatovic, J. Van Damme, Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells, Eur. Cytokine Net., in press.
60. Turner L., Scotton C., Negus R., and Balkwill F. Hypoxia inhibits macrophage migration. Eur. J. Immunol. 29 (1999) 2280-2287
61. Wang J., Wang J., Dai J., Jung Y., Wei C.L., Wang Y., et al. A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res. 67 (2007) 149-159
62. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
63. Wiley H.E., Gonzalez E.B., Maki W., Wu M.T., and Hwang S.T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst. 93 (2001) 1638-1643
64. Gunther K., Leier J., Henning G., Dimmler A., Weissbach R., Hohenberger W., et al. Prediction of lymph node metastasis in colorectal carcinoma by expression of chemokine receptor CCR7. Int. J. Cancer 116 (2005) 726-733
65. Mashino K., Sadanaga N., Yamaguchi H., Tanaka F., Ohta M., Shibuta K., et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62 (2002) 2937-2941
66. Chavey C., Bibeau F., Gourgou-Bourgade S., Burlinchon S., Boissiere F., Laune D., et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 9 (2007) R15
67. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6 (2000) 3282-3289
68. Saji H., Koike M., Yamori T., Saji S., Seiki M., Matsushima K., et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92 (2001) 1085-1091
69. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96 (2000) 34-40
70. Nam J.S., Kang M.J., Suchar A.M., Shimamura T., Kohn E.A., Michalowska A.M., et al. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res. 66 (2006) 7176-7184
71. Freund A., Chauveau C., Brouillet J.P., Lucas A., Lacroix M., Licznar A., et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22 (2003) 256-265
72. Lin Y., Huang R., Chen L., Li S., Shi Q., Jordan C., et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int. J. Cancer 109 (2004) 507-515
73. Freund A., Jolivel V., Durand S., Kersual N., Chalbos D., Chavey C., et al. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23 (2004) 6105-6114
74. Kim S.W., Hayashi M., Lo J.F., Fearns C., Xiang R., Lazennec G., et al. Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8. Cancer Res. 65 (2005) 8784-8791
75. Luboshits G., Shina S., Kaplan O., Engelberg S., Nass D., Lifshitz-Mercer B., et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59 (1999) 4681-4687
76. Yaal-Hahoshen N., Shina S., Leider-Trejo L., Barnea I., Shabtai E.L., Azenshtein E., et al. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin. Cancer Res. 12 (2006) 4474-4480
77. Goldberg-Bittman L., Neumark E., Sagi-Assif O., Azenshtein E., Meshel T., Witz I.P., et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol. Lett. 92 (2004) 171-178
78. Walser T.C., Rifat S., Ma X., Kundu N., Ward C., Goloubeva O., et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 66 (2006) 7701-7707
79. Richmond A., and Thomas H.G. Purification of melanoma growth stimulatory activity. J. Cell Physiol. 129 (1986) 375-384
80. Balentien E., Mufson B.E., Shattuck R.L., Derynck R., and Richmond A. Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene 6 (1991) 1115-1124
81. Anisowicz A., Messineo M., Lee S.W., and Sager R. An NF-kappa B-like transcription factor mediates IL-1/TNF-alpha induction of gro in human fibroblasts. J. Immunol. 147 (1991) 520-527
82. Haskill S., Peace A., Morris J., Sporn S.A., Anisowicz A., Lee S.W., et al. Identification of three related human GRO genes encoding cytokine functions. Proc. Natl. Acad. Sci. USA 87 (1990) 7732-7736
83. Colombo M.P., Maccalli C., Mattei S., Melani C., Radrizzani M., and Parmiani G. Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res. 2 (1992) 181-189
84. Graves D.T., Barnhill R., Galanopoulos T., and Antoniades H.N. Expression of monocyte chemotactic protein-1 in human melanoma in vivo. Am. J. Pathol. 140 (1992) 9-14
85. Robledo M.M., Bartolome R.A., Longo N., Rodriguez-Frade J.M., Mellado M., Longo I., et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J. Biol. Chem. 276 (2001) 45098-450105
86. Payne A.S., and Cornelius L.A. The role of chemokines in melanoma tumor growth and metastasis. J. Invest. Dermatol. 118 (2002) 915-922
87. Kawada K., Sonoshita M., Sakashita H., Takabayashi A., Yamaoka Y., Manabe T., et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 64 (2004) 4010-4017
88. Longo-Imedio M.I., Longo N., Trevino I., Lazaro P., and Sanchez-Mateos P. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int. J. Cancer 117 (2005) 861-865
89. Owen J.D., Strieter R., Burdick M., Haghnegahdar H., Nanney L., Shattuck-Brandt R., et al. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int. J. Cancer 73 (1997) 94-103
90. Sager R., Anisowicz A., Pike M.C., Beckmann P., and Smith T. Structural, regulatory, and functional studies of the GRO gene and protein. Cytokines 4 (1992) 96-116
91. Bordoni R., Fine R., Murray D., and Richmond A. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes. J. Cell Biochem. 44 (1990) 207-219
92. Shattuck-Brandt R.L., and Richmond A. Enhanced degradation of I-kappa B alpha contributes to endogenous activation of NF-kappa B in Hs294T melanoma cells. Cancer Res. 57 (1997) 3032-3039
93. Schadendorf D., Moller A., Algermissen B., Worm M., Sticherling M., and Czarnetzki B.M. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151 (1993) 2667-2675
94. Gutman M., Singh R.K., Xie K., Bucana C.D., and Fidler I.J. Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res. 55 (1995) 2470-2475
95. Mrowietz U., Schwenk U., Maune S., Bartels J., Kupper M., Fichtner I., et al. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br. J. Cancer 79 (1999) 1025-1031
96. Torisu H., Ono M., Kiryu H., Furue M., Ohmoto Y., Nakayama J., et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int. J. Cancer 85 (2000) 182-188
97. Morales J., Homey B., Vicari A.P., Hudak S., Oldham E., Hedrick J., et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc. Natl. Acad. Sci. USA 96 (1999) 14470-14475
98. Homey B., Wang W., Soto H., Buchanan M.E., Wiesenborn A., Catron D., et al. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J. Immunol. 164 (2000) 3465-3470
99. Varney M.L., Li A., Dave B.J., Bucana C.D., Johansson S.L., and Singh R.K. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin. Exp. Metastasis 20 (2003) 723-731
100. Varney M.L., Johansson S.L., and Singh R.K. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol. 125 (2006) 209-216
101. Yang J., and Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 9 (2004) 846-855
102. Strieter R.M., Belperio J.A., Burdick M.D., Sharma S., Dubinett S.M., and Keane M.P. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann. NY Acad. Sci. 1028 (2004) 351-360
103. Yao P.L., Lin Y.C., Wang C.H., Huang Y.C., Liao W.Y., Wang S.S., et al. Autocrine and paracrine regulation of interleukin-8 expression in lung cancer cells. Am. J. Respir. Cell Mol. Biol. 32 (2005) 540-547
104. Pold M., Zhu L.X., Sharma S., Burdick M.D., Lin Y., Lee P.P., et al. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res. 64 (2004) 1853-1860
105. Wald O., Izhar U., Amir G., Avniel S., Bar-Shavit Y., Wald H., et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J. Immunol. 177 (2006) 6983-6990
106. Zhu Y.M., Bagstaff S.M., and Woll P.J. Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1beta and hypoxia in small cell lung cancer. Br. J. Cancer 94 (2006) 1936-1941
107. Hartmann T.N., Burger J.A., Glodek A., Fujii N., and Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24 (2005) 4462-4471
108. Strieter R.M., Polverini P.J., Arenberg D.A., Walz A., Opdenakker G., Van Damme J., et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leukoc. Biol. 57 (1995) 752-762
109. Hillinger S., Yang S.C., Batra R.K., Strieter R.M., Weder W., Dubinett S.M., et al. CCL19 reduces tumour burden in a model of advanced lung cancer. Br. J. Cancer 94 (2006) 1029-1034
110. Vaday G.G., Peehl D.M., Kadam P.A., and Lawrence D.M. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66 (2006) 124-134
111. Lu Y., Cai Z., Galson D.L., Xiao G., Liu Y., George D.E., et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66 (2006) 1311-1318
112. Lu Y., Cai Z., Xiao G., Liu Y., Keller E.T., Yao Z., et al. CCR2 expression correlates with prostate cancer progression. J. Cell Biochem. (2007)
113. Craig M.J., and Loberg R.D. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev. (2006)
114. Singh S., Singh U.P., Stiles J.K., Grizzle W.E., and Lillard Jr. J.W. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin. Cancer Res. 10 (2004) 8743-8750
115. Lee L.F., Louie M.C., Desai S.J., Yang J., Chen H.W., Evans C.P., et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 23 (2004) 2197-2205
116. Murphy C., McGurk M., Pettigrew J., Santinelli A., Mazzucchelli R., Johnston P.G., et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin. Cancer Res. 11 (2005) 4117-4127
117. Lu S., and Dong Z. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells. Prostate 66 (2006) 996-1004
118. Shen H., Schuster R., Lu B., Waltz S.E., and Lentsch A.B. Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 66 (2006) 1721-1728
119. Nagpal M.L., Davis J., and Lin T. Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biochim. Biophys. Acta 1762 (2006) 811-818
120. Shulby S.A., Dolloff N.G., Stearns M.E., Meucci O., and Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 64 (2004) 4693-4698
121. Cunha G.R., Hayward S.W., Wang Y.Z., and Ricke W.A. Role of the stromal microenvironment in carcinogenesis of the prostate. Int. J. Cancer 107 (2003) 1-10
122. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., and Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59 (1999) 5002-5011
123. Ao M., Franco O.E., Park D., Raman D., Williams K., and Hayward S.W. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 67 (2007) 4244-4253
124. Bandyopadhyay S., Zhan R., Chaudhuri A., Watabe M., Pai S.K., Hirota S., et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat. Med. 12 (2006) 933-938
125. Iiizumi M., Bandyopadhyay S., and Watabe K. Interaction of Duffy antigen receptor for chemokines and KAI1: a critical step in metastasis suppression. Cancer Res. 67 (2007) 1411-1414
126. Parmo-Cabanas M., Bartolome R.A., Wright N., Hidalgo A., Drager A.M., and Teixido J. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp. Cell Res. 294 (2004) 571-580
127. Aggarwal R., Ghobrial I.M., and Roodman G.D. Chemokines in multiple myeloma. Exp. Hematol. 34 (2006) 1289-1295
128. Pellegrino A., Antonaci F., Russo F., Merchionne F., Ribatti D., Vacca A., et al. CXCR3-binding chemokines in multiple myeloma. Cancer Lett. 207 (2004) 221-227
129. Pellegrino A., Ria R., Di Pietro G., Cirulli T., Surico G., Pennisi A., et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br. J. Haematol. 129 (2005) 248-256
130. Reddy S.V., Takahashi S., Dallas M., Williams R.E., Neckers L., and Roodman G.D. Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J. Bone Miner. Res. 9 (1994) 753-757
131. Lentzsch S., Gries M., Janz M., Bargou R., Dorken B., and Mapara M.Y. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101 (2003) 3568-3573
132. Su S., Mukaida N., Wang J., Zhang Y., Takami A., Nakao S., et al. Inhibition of immature erythroid progenitor cell proliferation by macrophage inflammatory protein-1alpha by interacting mainly with a C-C chemokine receptor, CCR1. Blood 90 (1997) 605-611
133. Menu E., Asosingh K., Indraccolo S., De Raeve H., Van Riet I., Van Valckenborgh E., et al. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 91 (2006) 605-612
134. Giuliani N., Bonomini S., Romagnani P., Lazzaretti M., Morandi F., Colla S., et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 91 (2006) 1489-1497
135. Bendre M.S., Gaddy-Kurten D., Mon-Foote T., Akel N.S., Skinner R.A., Nicholas R.W., et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 62 (2002) 5571-5579
136. Bendre M., Gaddy D., Nicholas R.W., and Suva L.J. Breast cancer metastasis to bone: it is not all about PTHrP. Clin. Orthop. Relat. Res. (2003) S39-S45
137. Bendre M.S., Montague D.C., Peery T., Akel N.S., Gaddy D., and Suva L.J. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33 (2003) 28-37
138. Bendre M.S., Margulies A.G., Walser B., Akel N.S., Bhattacharrya S., Skinner R.A., et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappa B ligand pathway. Cancer Res. 65 (2005) 11001-11009
139. Biswas P., Delfanti F., Bernasconi S., Mengozzi M., Cota M., Polentarutti N., et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 91 (1998) 258-265
140. Arendt B.K., Velazquez-Dones A., Tschumper R.C., Howell K.G., Ansell S.M., Witzig T.E., et al. Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells. Leukemia 16 (2002) 2142-2147
141. Vande Broek I., Asosingh K., Vanderkerken K., Straetmans N., Van Camp B., and Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br. J. Cancer 88 (2003) 855-862
142. Nakagawa H., Liyanarachchi S., Davuluri R.V., Auer H., Martin Jr. E.W., de la Chapelle A., et al. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene 23 (2004) 7366-7377
143. Baier P.K., Eggstein S., Wolff-Vorbeck G., Baumgartner U., and Hopt U.T. Chemokines in human colorectal carcinoma. Anticancer Res. 25 (2005) 3581-3584
144. Chiu S.T., Hsieh F.J., Chen S.W., Chen C.L., Shu H.F., and Li H. Clinicopathologic correlation of up-regulated genes identified using cDNA microarray and real-time reverse transcription-PCR in human colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 437-443
145. Mitsuyama K., Tsuruta O., Tomiyasu N., Takaki K., Suzuki A., Masuda J., et al. Increased circulating concentrations of growth-related oncogene (GRO)-alpha in patients with inflammatory bowel disease. Dig. Dis. Sci. 51 (2006) 173-177
146. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
147. Kawada K., Hosogi H., Sonoshita M., Sakashita H., Manabe T., Shimahara Y., et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene (2007)
148. Zipin-Roitman A., Meshel T., Sagi-Assif O., Shalmon B., Avivi C., Pfeffer R.M., et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res. 67 (2007) 3396-3405
149. Scotton C.J., Wilson J.L., Scott K., Stamp G., Wilbanks G.D., Fricker S., et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62 (2002) 5930-5938
150. Porcile C., Bajetto A., Barbero S., Pirani P., and Schettini G. CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line. Ann. NY Acad. Sci. 1030 (2004) 162-169
151. Szlosarek P.W., Grimshaw M.J., Wilbanks G.D., Hagemann T., Wilson J.L., Burke F., et al. Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int. J. Cancer 121 (2007) 2760-2765
152. Kulbe H., Hagemann T., Szlosarek P.W., Balkwill F.R., and Wilson J.L. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res. 65 (2005) 10355-10362
153. Kulbe H., Thompson R., Wilson J.L., Robinson S., Hagemann T., Fatah R., et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 67 (2007) 585-592
154. Sica A., Saccani A., Bottazzi B., Bernasconi S., Allavena P., Gaetano B., et al. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J. Immunol. 164 (2000) 733-738
155. Kryczek I., Lange A., Mottram P., Alvarez X., Cheng P., Hogan M., et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65 (2005) 465-472
156. Curiel T.J., Cheng P., Mottram P., Alvarez X., Moons L., Evdemon-Hogan M., et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64 (2004) 5535-5538
157. Moscova M., Marsh D.J., and Baxter R.C. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res. 66 (2006) 1376-1383
158. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., and Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. USA 98 (2001) 12072-12077
159. Krtolica A., and Campisi J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int. J. Biochem. Cell Biol. 34 (2002) 1401-1414
160. Yang G., Rosen D.G., Zhang Z., Bast Jr. R.C., Mills G.B., Colacino J.A., et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. USA 103 (2006) 16472-16477
161. Mantovani A., Sozzani S., Locati M., Allavena P., and Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23 (2002) 549-555
162. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 4 (2004) 540-550
163. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappa B and enhanced IRF-3/STAT1 activation). Blood 107 (2006) 2112-2122
164. Sica A., Schioppa T., Mantovani A., and Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42 (2006) 717-727
165. Nesbit M., Schaider H., Miller T.H., and Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J. Immunol. 166 (2001) 6483-6490
166. Monti P., Leone B.E., Marchesi F., Balzano G., Zerbi A., Scaltrini F., et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 63 (2003) 7451-7461
167. Moran C.J., Arenberg D.A., Huang C.C., Giordano T.J., Thomas D.G., Misek D.E., et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin. Cancer Res. 8 (2002) 3803-3812
168. Azenshtein E., Luboshits G., Shina S., Neumark E., Shahbazian D., Weil M., et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 62 (2002) 1093-1102
169. Milliken D., Scotton C., Raju S., Balkwill F., and Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. 8 (2002) 1108-1114
170. Schutyser E., Struyf S., Proost P., Opdenakker G., Laureys G., Verhasselt B., et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J. Biol. Chem. 277 (2002) 24584-24593
171. Adema G.J., Hartgers F., Verstraten R., de Vries E., Marland G., Menon S., et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 387 (1997) 713-717
172. Kleeff J., Kusama T., Rossi D.L., Ishiwata T., Maruyama H., Friess H., et al. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81 (1999) 650-657
173. Robinson S.C., Scott K.A., and Balkwill F.R. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur. J. Immunol. 32 (2002) 404-412
174. Azenshtein E., Meshel T., Shina S., Barak N., Keydar I., and Ben-Baruch A. The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Lett. 217 (2005) 73-86
175. Allavena P., Sica A., Vecchi A., Locati M., Sozzani S., and Mantovani A. The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol. Rev. 177 (2000) 141-149
176. Fushimi T., Kojima A., Moore M.A., and Crystal R.G. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105 (2000) 1383-1393
177. Scarpino S., Stoppacciaro A., Ballerini F., Marchesi M., Prat M., Stella M.C., et al. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 156 (2000) 831-837
178. Vicari A.P., Treilleux I., and Lebecque S. Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin. Cancer Biol. 14 (2004) 161-169
179. Shellenberger T.D., Wang M., Gujrati M., Jayakumar A., Strieter R.M., Burdick M.D., et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 64 (2004) 8262-8270
180. Hirao M., Onai N., Hiroishi K., Watkins S.C., Matsushima K., Robbins P.D., et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 60 (2000) 2209-2217
181. Yang S.C., Batra R.K., Hillinger S., Reckamp K.L., Strieter R.M., Dubinett S.M., et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 66 (2006) 3205-3213
182. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
183. Remmel E., Terracciano L., Noppen C., Zajac P., Heberer M., Spagnoli G.C., et al. Modulation of dendritic cell phenotype and mobility by tumor cells in vitro. Hum. Immunol. 62 (2001) 39-49
184. Sallusto F., Lanzavecchia A., and Mackay C.R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 19 (1998) 568-574
185. Negus R.P., Stamp G.W., Hadley J., and Balkwill F.R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150 (1997) 1723-1734
186. Giovarelli M., Cappello P., Forni G., Salcedo T., Moore P.A., LeFleur D.W., et al. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J. Immunol. 164 (2000) 3200-3206
187. Vicari A.P., Ait-Yahia S., Chemin K., Mueller A., Zlotnik A., and Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165 (2000) 1992-2000
188. Viola A., Contento R.L., and Molon B. T cells and their partners: the chemokine dating agency. Trends Immunol. 27 (2006) 421-427
189. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J. Immunol. 178 (2007) 2883-2892
190. Balkwill F. Chemokine biology in cancer. Semin. Immunol. 15 (2003) 49-55
191. Gu L., Tseng S., Horner R.M., Tam C., Loda M., and Rollins B.J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404 (2000) 407-411
192. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004) 942-949
193. Wei S., Kryczek I., Zou L., Daniel B., Cheng P., Mottram P., et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 65 (2005) 5020-5026
194. Hirose K., Hakozaki M., Nyunoya Y., Kobayashi Y., Matsushita K., Takenouchi T., et al. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br. J. Cancer 72 (1995) 708-714
195. Lee L.F., Hellendall R.P., Wang Y., Haskill J.S., Mukaida N., Matsushima K., et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J. Immunol. 164 (2000) 2769-2775
196. Fioretti F., Fradelizi D., Stoppacciaro A., Ramponi S., Ruco L., Minty A., et al. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J. Immunol. 161 (1998) 342-346
197. Nokihara H., Yanagawa H., Nishioka Y., Yano S., Mukaida N., Matsushima K., et al. Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice. Cancer Res. 60 (2000) 7002-7007
198. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 (2002) 15-18
199. Folkman J., Watson K., Ingber D., and Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 (1989) 58-61
200. Naumov G.N., Akslen L.A., and Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5 (2006) 1779-1787
201. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324 (1991) 1-8
202. Weidner N., Carroll P.R., Flax J., Blumenfeld W., and Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143 (1993) 401-409
203. Kumar R., and Fidler I.J. Angiogenic molecules and cancer metastasis. In Vivo 12 (1998) 27-34
204. Iivanainen E., Kahari V.M., Heino J., and Elenius K. Endothelial cell-matrix interactions. Microsc. Res. Tech. 60 (2003) 13-22
205. Genis L., Galvez B.G., Gonzalo P., and Arroyo A.G. MT1-MMP: universal or particular player in angiogenesis?. Cancer Metastasis Rev. 25 (2006) 77-86
206. Benelli R., Lorusso G., Albini A., and Noonan D.M. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr. Pharm. Des. 12 (2006) 3101-3115
207. Gomperts B.N., and Strieter R.M. Chemokine-directed metastasis. Contrib. Microbiol. 13 (2006) 170-190
208. Kakinuma T., and Hwang S.T. Chemokines, chemokine receptors, and cancer metastasis. J. Leukoc. Biol. 79 (2006) 639-651
209. Strieter R.M., Burdick M.D., Mestas J., Gomperts B., Keane M.P., and Belperio J.A. Cancer CXC chemokine networks and tumour angiogenesis. Eur. J. Cancer 42 (2006) 768-778
210. Ruiz de Almodovar C., Luttun A., and Carmeliet P. An SDF-1 trap for myeloid cells stimulates angiogenesis. Cell 124 (2006) 18-21
211. Rosenkilde M.M., and Schwartz T.W. The chemokine system - a major regulator of angiogenesis in health and disease. APMIS 112 (2004) 481-495
212. Salcedo R., and Oppenheim J.J. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10 (2003) 359-370
213. Romagnani P., Lasagni L., Annunziato F., Serio M., and Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 25 (2004) 201-209
214. Heidemann J., Ogawa H., Dwinell M.B., Rafiee P., Maaser C., Gockel H.R., et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 278 (2003) 8508-8515
215. Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270 (1995) 27348-27357
216. Strieter R.M., Polverini P.J., Arenberg D.A., and Kunkel S.L. The role of CXC chemokines as regulators of angiogenesis. Shock 4 (1995) 155-160
217. Moore B.B., Arenberg D.A., Addison C.L., Keane M.P., Polverini P.J., and Strieter R.M. CXC chemokines mechanism of action in regulating tumor angiogenesis. Angiogenesis 2 (1998) 123-134
218. Nor J.E., Christensen J., Mooney D.J., and Polverini P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154 (1999) 375-384
219. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat. Rev. Immunol. 2 (2002) 664-674
220. Schruefer R., Lutze N., Schymeinsky J., and Walzog B. Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H1186-H1192
221. Addison C.L., Daniel T.O., Burdick M.D., Liu H., Ehlert J.E., Xue Y.Y., et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J. Immunol. 165 (2000) 5269-5277
222. Shyamala V., and Khoja H. Interleukin-8 receptors R1 and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells. Biochemistry 37 (1998) 15918-15924
223. Wente M.N., Keane M.P., Burdick M.D., Friess H., Buchler M.W., Ceyhan G.O., et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett. 241 (2006) 221-227
224. Keane M.P., Belperio J.A., Xue Y.Y., Burdick M.D., and Strieter R.M. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J. Immunol. 172 (2004) 2853-2860
225. Maione T.E., Gray G.S., Petro J., Hunt A.J., Donner A.L., Bauer S.I., et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247 (1990) 77-79
226. Struyf S., Burdick M.D., Proost P., Van Damme J., and Strieter R.M. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ. Res. 95 (2004) 855-857
227. Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin. Thromb. Hemost. 30 (2004) 379-385
228. Bikfalvi A., and Gimenez-Gallego G. The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin. Thromb. Hemost. 30 (2004) 137-144
229. Addison C.L., Arenberg D.A., Morris S.B., Xue Y.Y., Burdick M.D., Mulligan M.S., et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum. Genet. Ther. 11 (2000) 247-261
230. Strieter R.M., Kunkel S.L., Arenberg D.A., Burdick M.D., and Polverini P.J. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 210 (1995) 51-57
231. Salcedo R., Resau J.H., Halverson D., Hudson E.A., Dambach M., Powell D., et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 14 (2000) 2055-2064
232. Romagnani P., Annunziato F., Lasagni L., Lazzeri E., Beltrame C., Francalanci M., et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 107 (2001) 53-63
233. Burdick M.D., Murray L.A., Keane M.P., Xue Y.Y., Zisman D.A., Belperio J.A., et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am. J. Respir. Crit. Care Med. 171 (2005) 261-268
234. Heidemann J., Ogawa H., Rafiee P., Lugering N., Maaser C., Domschke W., et al. Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G1059-G1068
235. Salcedo R., Wasserman K., Young H.A., Grimm M.C., Howard O.M., Anver M.R., et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am. J. Pathol. 154 (1999) 1125-1135
236. Guleng B., Tateishi K., Ohta M., Kanai F., Jazag A., Ijichi H., et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res. 65 (2005) 5864-5871
237. Schrader A.J., Lechner O., Templin M., Dittmar K.E., Machtens S., Mengel M., et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br. J. Cancer 86 (2002) 1250-1256
238. Grunewald M., Avraham I., Dor Y., Bachar-Lustig E., Itin A., Jung S., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124 (2006) 175-189
239. De Palma M., Venneri M.A., Roca C., and Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9 (2003) 789-795
240. Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85 (1999) 221-228
241. Yan L., Anderson G.M., DeWitte M., and Nakada M.T. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur. J. Cancer 42 (2006) 793-802
242. Goede V., Brogelli L., Ziche M., and Augustin H.G. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int. J. Cancer 82 (1999) 765-770
243. Galvez B.G., Genis L., Matias-Roman S., Oblander S.A., Tryggvason K., Apte S.S., et al. Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte chemoattractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis. J. Biol. Chem. 280 (2005) 1292-1298
244. Hong K.H., Ryu J., and Han K.H. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105 (2005) 1405-1407
245. Ma J., Wang Q., Fei T., Han J.D., and Chen Y.G. MCP-1 mediates TGF-{beta}-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood (2006)
246. Liss C., Fekete M.J., Hasina R., Lam C.D., and Lingen M.W. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int. J. Cancer 93 (2001) 781-785
247. Bernardini G., Spinetti G., Ribatti D., Camarda G., Morbidelli L., Ziche M., et al. I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood 96 (2000) 4039-4045
248. Salcedo R., Young H.A., Ponce M.L., Ward J.M., Kleinman H.K., Murphy W.J., et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J. Immunol. 166 (2001) 7571-7578
249. Hwang J., Kim C.W., Son K.N., Han K.Y., Lee K.H., Kleinman H.K., et al. Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo. FEBS Lett. 570 (2004) 47-51
250. Hwang J., Son K.N., Kim C.W., Ko J., Na D.S., Kwon B.S., et al. Human CC chemokine CCL23, a ligand for CCR1, induces endothelial cell migration and promotes angiogenesis. Cytokine 30 (2005) 254-2563
251. Strasly M., Doronzo G., Capello P., Valdembri D., Arese M., Mitola S., et al. CCL16 activates an angiogenic program in vascular endothelial cells. Blood 103 (2004) 40-49
252. Adler E.P., Lemken C.A., Katchen N.S., and Kurt R.A. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol. Lett. 90 (2003) 187-194
253. Son K.N., Hwang J., Kwon B.S., and Kim J. Human CC chemokine CCL23 enhances expression of matrix metalloproteinase-2 and invasion of vascular endothelial cells. Biochem. Biophys. Res. Commun. 340 (2006) 498-504
254. Arenberg D.A., Zlotnick A., Strom S.R., Burdick M.D., and Strieter R.M. The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Cancer Immunol. Immunother. 49 (2001) 587-592
255. Umehara H., Bloom E.T., Okazaki T., Nagano Y., Yoshie O., and Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 34-40
256. Imaizumi T., Yoshida H., and Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J. Atheroscler. Thromb. 11 (2004) 15-21
257. Volin M.V., Woods J.M., Amin M.A., Connors M.A., Harlow L.A., and Koch A.E. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am. J. Pathol. 159 (2001) 1521-1530
258. Pruenster M., and Rot A. Throwing light on DARC. Biochem. Soc. Trans. 34 (2006) 1005-1008
259. Nibbs R., Graham G., and Rot A. Chemokines on the move: control by the chemokine "interceptors" Duffy blood group antigen and D6. Semin. Immunol. 15 (2003) 287-294
260. Du J., Luan J., Liu H., Daniel T.O., Peiper S., Chen T.S., et al. Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. J. Leukoc. Biol. 71 (2002) 141-153
261. Addison C.L., Belperio J.A., Burdick M.D., and Strieter R.M. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 4 (2004) 28
262. Wang J., Ou Z.L., Hou Y.F., Luo J.M., Shen Z.Z., Ding J., et al. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 25 (2006) 7201-7211
263. Shen H., Schuster R., Stringer K.F., Waltz S.E., and Lentsch A.B. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J. 20 (2006) 59-64
264. Dolberg D.S., and Bissell M.J. Inability of Rous sarcoma virus to cause sarcomas in the avian embryo. Nature 309 (1984) 552-556
265. Dolberg D.S., Hollingsworth R., Hertle M., and Bissell M.J. Wounding and its role in RSV-mediated tumor formation. Science 230 (1985) 676-678
266. Martins-Green M., Boudreau N., and Bissell M.J. Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res. 54 (1994) 4334-4341
267. Ronnov-Jessen L., Petersen O.W., Koteliansky V.E., and Bissell M.J. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J. Clin. Invest. 95 (1995) 859-873
268. Bissell M.J., and Radisky D. Putting tumours in context. Nat. Rev. Cancer 1 (2001) 46-54
269. Tlsty T.D., and Hein P.W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 11 (2001) 54-59
270. Boyd R.S., and Balkwill F.R. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br. J. Cancer 80 (1999) 315-321
271. Bierie B., and Moses H.L. Under pressure: stromal fibroblasts change their ways. Cell 123 (2005) 985-987
272. Sugimoto H., Mundel T.M., Kieran M.W., and Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. (2006) 5
273. Streuli C.H., Schmidhauser C., Kobrin M., Bissell M.J., and Derynck R. Extracellular matrix regulates expression of the TGF-beta 1 gene. J. Cell Biol. 120 (1993) 253-260
274. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 (2004) 848-851
275. Sieweke M.H., Thompson N.L., Sporn M.B., and Bissell M.J. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science 248 (1990) 1656-1660
276. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. USA 101 (2004) 4966-4971
277. Egeblad M., Littlepage L.E., and Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harb. Symp. Quant. Biol. 70 (2005) 383-388
278. Moskovits N., Kalinkovich A., Bar J., Lapidot T., and Oren M. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 66 (2006) 10671-10676
279. Homey B., Wong W., Soto H., Buchanan M.E., Wiesenborn A., Carton D., et al. Culting edge: the orphan chemokine receptor G-protein coupled receptor-2 (GPR-2,CCR10) binds the skin-associated CCL27 (CTACK/ALP/ILL). J. Immunol. 164 (2000) 3465-3470
280. E Luker K., and Luker G.D. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 238 (2006) 30-41